3-(4-tert-butylbenzyloxy)benzaldehyde | 172931-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4-tert-butylbenzyloxy)benzaldehyde
• 英文别名: 3-[4-(t-butyl)benzyloxy]benzaldehyde；3-[(4-tert-butylphenyl)methoxy]benzaldehyde
• CAS: 172931-91-8
• 化学式: C₁₈H₂₀O₂
• 分子量: 268.356
• InChiKey: QXLDRBGJFJMTIW-UHFFFAOYSA-N

物化性质

• 沸点：
  397.1±22.0 °C(Predicted)
• 密度：
  1.062±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4-tert-butylbenzyloxy)benzaldehyde 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 N'-(4-((4-(tert-butyl)benzyl)oxy)benzylidene)-3,4,5-trihydroxybenzohydrazide
  参考文献：
  名称：

  Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice

  摘要：

  Sphingosine kinase (SphK)-catalyzed production of sphingosine-1-phosphate (S1P) regulates cell growth, survival and proliferation as well as inflammatory status in animals. In recent study we reported the N'-(3-(benzyloxy)benzylidene)-3,4,5-trihydroxybenzohydrazide scaffold as a potent SphK inhibitor. As a continuation of these efforts, 51 derivatives were synthesized and evaluated by SphK1/2 inhibitory activities for structure-activity relationship (SAR) study. Among them, 33 was identified as the most potent SphK inhibitor. Potency of 33 was also observed to efficiently decrease SphK1/2 expression in human colorectal cancer cells (HCT116) and significantly inhibit dextran sodium sulfate (DSS)-induced colitis as well as the decreased expression of interleukin (IL)-6 and cyclooxygenase-2 (COX-2) in mouse models. Collectively, 33 was validated as an effective SphK inhibitor, which can be served as anti-inflammatory agent to probably treat inflammatory bowel diseases in human. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.05.047
• 作为产物：
  描述：

  4-叔丁基苄溴 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 3-(4-tert-butylbenzyloxy)benzaldehyde
  参考文献：
  名称：

  含苄氧基苯基的酚类化合物、其制备方法及用 途

  摘要：

  本发明公开了含苄氧基苯基的酚类化合物、其制备方法及用途，具体公开了一类含苄氧基苯基的酚类化合物(I)，药理试验证明，本发明的酚类化合物对鞘氨醇激酶SphK有较强的抑制活性，部分化合物对肿瘤、DSS诱导的炎症性肠病具有一定的抑制作用。该类化合物与其药用制剂可以用于制备治疗一系列癌症、炎症性疾病的药物，例如结肠癌、肺癌、乳腺癌、肝癌、胃癌、炎症性肠病、肝炎、哮喘、慢性阻塞性肺病、类风湿性关节炎、多发性硬化症。本发明还涉及这些化合物的制备方法。

  公开号：

  CN107151220B

文献信息

• Benzylidene rhodanines
  申请人：Eli Lilly and Company

  公开号：US05747517A1

  公开（公告）日：1998-05-05

  This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with .beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

  本发明提供了一种新型的苄亚胺硫代缩苹果酸，它们作为治疗或预防与β-淀粉样肽相关疾病的药物很有用。本发明还提供了治疗或预防阿尔茨海默病的方法，该方法包括向需要的哺乳动物施用有效量的本发明的一种或多种苄亚胺硫代缩苹果酸。
• Thrombopoietin mimetics
  申请人：——

  公开号：US20030083361A1

  公开（公告）日：2003-05-01

  Invented are non-peptide TPO mimetics. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected substituted naphthimidazole derivative.

  发明了非肽类TPO类似物。还发明了一种治疗血小板减少症的方法，包括在需要的哺乳动物，包括人类中，向该哺乳动物施用所选取代萘咪唑衍生物的有效量。
• Treatment of alzheimer's disease employing inhibitors of cathepsin D
  申请人：Eli Lilly and Company

  公开号：US06251928B1

  公开（公告）日：2001-06-26

  This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with &bgr;-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

  本发明提供了一种新型的苯甲醛基硫氰酸酯，可用作治疗或预防与β-淀粉样肽相关的疾病的药剂。本发明还提供了治疗或预防阿尔茨海默病的方法，包括向需要的哺乳动物中给予本发明中的一种或多种苯甲醛基硫氰酸酯的有效量。
• Treatment of Alzheimer's disease employing inhibitors of cathepsin D
  申请人：ELI LILLY AND COMPANY

  公开号：EP0677517A1

  公开（公告）日：1995-10-18

  This invention provides novel benzylidene rhodanines of the formula wherein nis 0, 1, 2, 3, or 4; qis 0, 1, 2, 3, or 4; Ais -O, -NH-, or -S(O)m-;    where m is 0, 1, or 2; R¹is hydrogen, C₁-C₆ alkyl, di(C₁-C₆ alkyl)amino-, amino, (C₁-C₆ alkyl)amino-, cyano(C₁-C₆ alkyl)-, or carboxy(C₁-C₆ alkylidenyl)-; Ris phenyl, oxazolyl, benzophenonyl, or naphthyl optionally substituted with one or more substituents, which are useful as agents in treating or preventing conditions associated with β-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention. This invention also provides methods for reducing blood glucose concentrations which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.

  本发明提供了式如下的新型亚苄基罗丹宁 式中 n为0、1、2、3或4； q为0、1、2、3或4； A是-O、-NH-或-S(O)m-； 其中 m 为 0、1 或 2； R¹是氢、C₁-C₆烷基、二(C₁-C₆烷基)氨基、氨基、(C₁-C₆烷基)氨基、氰基(C₁-C₆烷基)-或羧基(C₁-C₆亚烷基)-； 里氏苯基、恶唑基、二苯甲酮基或任选被一个或多个取代基取代的萘基，可用作治疗或预防与 β 淀粉样肽相关的疾病的药物。本发明进一步提供了治疗或预防阿尔茨海默病的方法，其中包括向有需要的哺乳动物施用有效量的一种或多种本发明的亚苄基罗丹宁。本发明还提供了降低血糖浓度的方法，其中包括向有需要的哺乳动物施用有效量的一种或多种本发明的亚苄基罗丹宁。
• THROMBOPOIETIN MIMETICS
  申请人：SmithKline Beecham Corporation

  公开号：EP1244446A1

  公开（公告）日：2002-10-02